Drug Trial Radar · NCT07817121
A First-in-human Trial of SZN-8141 in Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Aug 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Surrozen Operating, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DUET (Cl-8141-1001) is a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics (how the body processes the study drug), and preliminary biological activity of SZN-8141 in people with diabetic macular edema (DME). In this study, small groups of participants with DME (approximately three participants per dose group) will receive a single injection of SZN-8141 into the eye and will be followed for approximately 3 months. During the trial, participants will undergo regular assessments to monitor their overall health and eye condition. These assessments include eye examinations, vision testing, retinal imaging, laboratory testing, and blood sample collection to measure levels of SZN-8141 in the bloodstream and to assess whether the body develops anti-drug antibodies. The trial uses an ascending-dose design, in which successive groups of participants receive increasing dose levels of SZN-8141. Safety and tolerability data from each dose group will be reviewed before the next higher dose level is evaluated.
Conditions
- Diabetic Macular Edema (DME)
Interventions
SZN-8141 for InjectionBiological
SZN-8141 for Injection is a humanized antibody formulated for IVT administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse eventsTime frame: Up to 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.